DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DWTX DOGWOOD THERAPEUTICS INC

交易中 10-08 13:52:18 EDT

1.46

+0.03

+2.10%

最高1.48	最低1.43	成交量2.89万
今开1.48	昨收1.43	日振幅3.50%
总市值4,963万	流通市值848.25万	总股本3,399万
成交额4.21万	换手率0.50%	流通股本580.99万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":1.46,"timestamp":1791480907979,"preClose":1.43,"halted":0,"volume":28899,"delay":0,"changeRate":0.020979020979020997,"floatShares":5809900,"shares":33992600,"eps":-8.9478,"marketStatus":"交易中","change":0.03,"latestTime":"10-08 13:52:18 EDT","open":1.48,"high":1.48,"low":1.43,"amount":42116.4431532,"amplitude":0.034965,"askPrice":1.47,"askSize":100,"bidPrice":1.43,"bidSize":4609,"shortable":3,"etf":0,"ttmEps":-8.9478,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":1.43,"preHourTrading":{"tag":"盘前","latestPrice":1.5155,"preClose":1.43,"latestTime":"09:20 EDT","volume":2333,"amount":3646.646976,"timestamp":1791465658177,"change":0.0855,"changeRate":0.05979,"amplitude":0.093986},"postHourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.43,"latestTime":"19:41 EDT","volume":6039,"amount":8481.0274,"timestamp":1791416497224,"change":-0.03,"changeRate":-0.020979,"amplitude":0.020979},"volumeRatio":0.571008},"requestUrl":"/m/hq/s/DWTX/tweets","defaultTab":"tweets","newsList":[{"id":"1113001000","title":"Dogwood完成Halneuron® 2B期化疗诱发神经病变试验首批200名患者入组；关键数据预计2026年秋季公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1113001000","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113001000?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:32","pubTimestamp":1784550725,"startTime":"0","endTime":"0","summary":"在针对化疗诱发神经病变的Halneuron® 2B期临床试验中，Dogwood Therapeutics已成功完成首批200名患者的入组工作。这项持续进行的试验预计将在2026年秋季获得关键性数据结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153907881","title":"Dogwood Therapeutics任命奥博资本风险合伙人Iain Dukes为科学顾问委员会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=1153907881","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153907881?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:46","pubTimestamp":1782823577,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc. 宣布了一项重要人事任命，Iain Dukes 将担任其科学顾问委员会主席一职。Dukes 先生目前是知名投资机构奥博资本的风险合伙人，他在生物技术和生命科学领域拥有深厚的专业背景与丰富的行业经验。此次任命旨在进一步加强 Dogwood Therapeutics 的科学战略指导与研发能力。公司期望借助 Dukes 先生在药物开发、企业战略及投资方面的专长，加速其治疗管线的推进，并为未来的科学决策提供关键洞见。Dukes 先生的加入，预计将为 Dogwood Therapeutics 带来更广阔的行业视野和战略资源。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137042063","title":"Dogwood Therapeutics Inc - 扩展试验数据将支持2027年上半年三期项目向FDA提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1137042063","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137042063?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:46","pubTimestamp":1779108396,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc 宣布，其扩展试验数据将为公司在2027年上半年向美国食品药品监督管理局（FDA）提交三期项目申请提供关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159504779","title":"Dogwood Therapeutics 2026年第一季度净亏损500万美元，合每股0.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159504779","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159504779?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:35","pubTimestamp":1778762111,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc公布2026年第一季度财务业绩，归属于普通股股东的净亏损为500万美元，摊薄后每股亏损0.15美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141459489","title":"Dogwood Therapeutics 宣布达成历史抗病毒资产合作，潜在价值高达1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141459489","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141459489?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:34","pubTimestamp":1778762087,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc 宣布，已就一批历史抗病毒资产达成一项合作协议。该合作潜在价值最高可达1亿美元，标志着公司在盘活非核心资产、挖掘其潜在价值方面取得了重要进展。此次合作旨在通过外部专业力量，进一步开发这些资产的商业潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191715043","title":"Dogwood Therapeutics 达成抗病毒资产全球开发与商业化合作 潜在价值高达1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191715043","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191715043?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:01","pubTimestamp":1776949299,"startTime":"0","endTime":"0","summary":"DOGWOOD THERAPEUTICS INC 近日宣布，已就旗下抗病毒资产达成一项全球范围内的开发与商业化战略合作伙伴关系。此次合作蕴含巨大潜力，其总价值有望攀升至1亿美元，标志着公司在抗病毒治疗领域迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176419965","title":"Dogwood Therapeutics旗下Serpin Pharma获美国国家癌症研究所250万美元资助 用于SP16一期B阶段试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1176419965","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176419965?lang=zh_cn&edition=full","pubTime":"2026-04-15 21:15","pubTimestamp":1776258902,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc旗下子公司Serpin Pharma近日宣布，已获得美国国家癌症研究所（National Cancer Institute）提供的250万美元资助。该项资金将专项用于支持SP16药物的一期B阶段临床试验（Phase 1B Trial）的推进工作。\n该资助标志着SP16在肿瘤治疗领域的研发取得重要进展。一期B阶段试验将重点评估SP16在特定患者群体中的安全性、耐受性及初步疗效，为后续临床研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158453332","title":"Dogwood Therapeutics与合作伙伴Serpin Pharma预计SP16药物1B期临床试验将于2026年年中启动患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1158453332","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158453332?lang=zh_cn&edition=full","pubTime":"2026-04-15 21:07","pubTimestamp":1776258439,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc及其合作伙伴Serpin Pharma近日宣布，针对SP16药物的1B期临床试验预计将于2026年中期正式启动患者招募工作。这一重要进展标志着该创新疗法在临床开发道路上迈出关键一步。\n两家公司透露，此次临床试验将重点评估SP16在特定患者群体中的安全性和有效性。该时间节点的确定基于前期研究数据的积极反馈以及监管沟通的顺利推进。研究人员表示，这一里程碑事件将为后续临床开发计划奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183833289","title":"Dogwood Therapeutics宣布FDA受理SP16研究性新药申请 用于治疗化疗引发疼痛及神经病变","url":"https://stock-news.laohu8.com/highlight/detail?id=1183833289","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183833289?lang=zh_cn&edition=full","pubTime":"2026-04-15 21:02","pubTimestamp":1776258152,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics公司宣布，美国食品药品监督管理局（FDA）已正式受理其SP16研究性新药（IND）申请。该申请旨在探索SP16用于治疗化疗引起的疼痛和神经病变的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.dwtx.com;www.dwtx.com","stockEarnings":[{"period":"1week","weight":0.0593},{"period":"1month","weight":-0.3755},{"period":"3month","weight":0.0142},{"period":"6month","weight":-0.2814},{"period":"1year","weight":-0.7885},{"period":"ytd","weight":-0.6563}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.1439},{"period":"1year","weight":0.1616},{"period":"ytd","weight":0.1398}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dogwood Therapeutics, Inc.最初于2012年2月28日在阿拉巴马州成立，后来改为内华达州公司。Dogwood是一家尚未盈利的生物制药公司，处于研发阶段，专注于发现和开发治疗疼痛和神经病变的新药。公司研发管线主要集中于慢性神经性疼痛和神经病变，其核心产品是Halneuron Nav1.7调节剂项目。该项目是一种专有的非阿片类镇痛方法，通过靶向电压门控钠通道Nav1.7来减轻疼痛。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.643793},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.153661},{"month":3,"riseRate":0.5,"avgChangeRate":0.00331},{"month":4,"riseRate":0.333333,"avgChangeRate":0.090085},{"month":5,"riseRate":0.5,"avgChangeRate":0.166607},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.023497},{"month":7,"riseRate":0.666667,"avgChangeRate":0.16521},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007149},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.184666},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.151744},{"month":11,"riseRate":0.8,"avgChangeRate":-0.028445},{"month":12,"riseRate":0.4,"avgChangeRate":-0.112321}],"exchange":"NASDAQ","name":"DOGWOOD THERAPEUTICS INC","nameEN":"DOGWOOD THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供DOGWOOD THERAPEUTICS INC(DWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"DOGWOOD THERAPEUTICS INC,DWTX,DOGWOOD THERAPEUTICS INC股票,DOGWOOD THERAPEUTICS INC股票老虎,DOGWOOD THERAPEUTICS INC股票老虎国际,DOGWOOD THERAPEUTICS INC行情,DOGWOOD THERAPEUTICS INC股票行情,DOGWOOD THERAPEUTICS INC股价,DOGWOOD THERAPEUTICS INC股市,DOGWOOD THERAPEUTICS INC股票价格,DOGWOOD THERAPEUTICS INC股票交易,DOGWOOD THERAPEUTICS INC股票购买,DOGWOOD THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供DOGWOOD THERAPEUTICS INC(DWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}